세계의 털세포 백혈병 치료 시장 : 규모, 점유율, 동향 분석 보고서 - 치료별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Hairy Cell Leukemia Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,272,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,662,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,443,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

털세포 백혈병 치료 시장의 성장과 동향 :

Grand View Research, Inc.의 조사 보고서에 따르면, 세계 털세포 백혈병 치료 시장 규모는 2030년까지 1억 4,770만 달러에 이를 전망이고, 예측 기간 동안 복합 연간 성장률(CAGR) 5.4%로 성장할 것으로 예측됩니다.

이 성장의 원동력은 특히 고령화 사회에서 털세포 백혈병(HCL)의 이환율의 상승이며, 이로써 효과적인 치료에 대한 수요가 높아지고 있습니다. 표적 치료제와 단클론항체와 같은 신규 치료제의 도입은 치료 옵션을 크게 확대하고, 환자의 예후를 개선하고, 시장 성장을 더욱 강화하고 있습니다. 특히 선진지역에서의 인지도 향상과 고급 의료 인프라의 정비도 환자가 최신 치료 옵션에 접근할 수 있도록 하기 위해 HCL 치료의 채용을 촉진하는데 중요한 역할을 하고 있습니다.

임상시험은 BRAF 억제제와 MEK 억제제와 같은 병용 요법이 치료 효과를 크게 향상시키는 것으로 나타났으며, HCL 환자에게 새로운 희망을 가져왔습니다. 또한, 현재 진행 중인 맞춤형 의료 연구는 개별 환자프로파일에 맞게 치료를 조정하는 것을 목표로 하며, 부작용을 최소화하면서 치료 성적을 개선할 수 있습니다. 이 접근법은 각 환자 고유의 요구에 대응하고보다 효과적이고 안전한 치료법으로 이어지기 때문에 특히 유망합니다.

2023년 9월 미국 국립의학 도서관에서 발표된 연구는 고전적인 HCL의 임상적 특징에 대한 추가 인사이트을 제공합니다. 이 연구는 비장종이 모든 환자의 가장 흔한 임상 특징(100%)이었습니다고 보고합니다. 다른 중요한 소견으로는 75% 환자에서 간종대, 58.33% 환자에서 범혈구 감소가 보였고 나머지 환자는 이혈구 감소를 보였습니다. 환자의 66.6% 말초 혈액 도말 표본(PBS)에서는 유모세포가 관찰되었고, 골수흡인(BMA)에서는 25%의 경우 드라이탭이 관찰되었습니다. 골수 천자 생검 소견에서는 92%의 환자에서 고세포성이었고, 극히 일부(8%)에서 저세포성을 보였습니다. 이러한 발견은 HCL의 복잡성을 강조하는 것이며, 특히이 질병의 다양한 증상과 진단 및 관리의 과제를 고려할 때 치료 접근법의 지속적인 연구와 혁신의 필요성을 강조합니다.

털세포 백혈병 치료 시장 보고서 하이라이트

• 표적 치료 부문은 2023년에 32.45%의 최대 점유율을 차지하며 예측 기간 동안 7.5%의 복합 연간 성장률(CAGR) 가장 빠른 성장이 예상됩니다.
• 병원 부문은 2023년 64.34%의 최대 점유율을 차지했습니다. 병원은 HCL의 효과적인 치료에 필수적인 종양 전문 의료를 포함한 종합적인 서비스를 제공하기 때문입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 털세포 백혈병 치료 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 털세포 백혈병 치료 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • 파이프라인 분석

제4장 털세포 백혈병 치료 시장 : 치료별 추정 및 동향 분석

• 털세포 백혈병 치료 시장 : 치료 대시보드
• 털세포 백혈병 치료 시장 : 치료 변동 분석
• 털세포 백혈병 치료 시장 : 치료 수익
• 화학요법
• 표적요법
• 면역요법
• 기타

제5장 털세포 백혈병 치료 시장 : 최종 용도별 추정 및 동향 분석

• 털세포 백혈병 치료 시장 : 최종 용도 대시보드
• 털세포 백혈병 치료 시장 : 최종 용도 변동 분석
• 털세포 백혈병 치료 시장 : 최종 용도 수익
• 병원
• 전문 클리닉
• 기타

제6장 털세포 백혈병 치료 시장 :지역별 추정 및 동향 분석, 치료별, 최종 용도별

• 지역 대시보드
• 시장 규모와 예측 동향 분석(2018년-2030년)
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 구도

• 기업/경쟁의 분류
• 벤더 상황
  • 주요 리셀러 및 채널 파트너 목록
  • 주요 고객
  • 주요 기업의 시장 점유율 분석(2023년)
• 기업 프로파일
  • Pfizer Inc
  • F. Hoffmann La Roche AG
  • Janssen Global Services
  • Emcure Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Amgen, Inc.
  • Hospira
  • AbbVie
  • AstraZeneca

BJH

영문 목차

영문목차

Hair Cell Leukemia Treatment Market Growth & Trends:

The global hairy cell leukemia treatment market size is estimated to reach USD 147.7 million by 2030, growing at a CAGR of 5.4% during the forecast period, according to a report by Grand View Research, Inc. This growth is driven by the rising incidence of hairy cell leukemia (HCL), particularly among aging populations, which increases the demand for effective treatments. The introduction of novel therapeutics, such as targeted therapies and monoclonal antibodies, has significantly expanded treatment options, improving patient outcomes and further fueling market growth. Enhanced awareness and the availability of advanced healthcare infrastructure, especially in developed regions, also play a crucial role in driving the adoption of HCL treatments, ensuring that patients can access the latest therapeutic options.

Clinical trials have shown that combination therapies, such as BRAF and MEK inhibitors, can significantly enhance treatment efficacy, offering new hope for patients with HCL. Moreover, ongoing research into personalized medicine aims to tailor treatments to individual patient profiles, potentially improving outcomes while minimizing side effects. This approach is particularly promising as it addresses each patient's unique needs, leading to more effective and safer therapies.

A study published by the National Library of Medicine in September 2023 provides further insights into the clinical features of classical HCL. The study reported that splenomegaly was all patients' most common clinical feature (100%). Other significant findings included hepatomegaly in 75% of patients and pancytopenia in 58.33%, with the remaining patients exhibiting bicytopenia. Hairy cells were observed in the peripheral blood smear (PBS) of 66.6% of patients, while bone marrow aspirates (BMA) resulted in a dry tap in 25% of cases. Bone marrow trephine biopsy findings indicated hypercellularity in 92% of patients, with a small percentage (8%) showing hypocellularity. These findings underscore the complexity of HCL and the necessity for continued research and innovation in treatment approaches, particularly in light of the disease's varied presentations and challenges in diagnosis and management.

Hairy Cell Leukemia Treatment Market Report Highlights:

• The targeted therapy segment held the largest share of 32.45% in 2023 and is also expected to grow at the fastest CAGR of 7.5% during the forecast period
• The hospitals segment held the largest share of 64.34% in 2023 as they provide a comprehensive range of services, including specialized oncology care, which is crucial for the effective treatment of HCL
• Some of the prominent players in market are Pfizer Inc; F. Hoffmann La Roche AG; Janssen Global Services; Emcure Pharmaceuticals; Dr. Reddy's Laboratories; Amgen, Inc.; Hospira; AbbVie; AstraZeneca

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database.
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Hairy Cell Leukemia Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Prevalence Of Hairy Cell Leukemia
    • 3.2.1.2. Advancements In Targeted Therapies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Treatment Costs
    • 3.2.2.2. Lack of Awareness and Diagnostic Challenges
• 3.3. Hairy Cell Leukemia Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Hairy Cell Leukemia Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Hairy Cell Leukemia Treatment Market: Treatment Dashboard
• 4.2. Hairy Cell Leukemia Treatment Market: Treatment Movement Analysis
• 4.3. Hairy Cell Leukemia Treatment Market by Treatment, Revenue (USD Million)
• 4.4. Chemotherapy
  • 4.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.5. Targeted Therapy
  • 4.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.6. Immunotherapy
  • 4.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.7. Other
  • 4.7.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 5. Hairy Cell Leukemia Treatment Market: End Use Estimates & Trend Analysis

• 5.1. Hairy Cell Leukemia Treatment Market: End Use Dashboard
• 5.2. Hairy Cell Leukemia Treatment Market: End Use Movement Analysis
• 5.3. Hairy Cell Leukemia Treatment Market by End Use, Revenue (USD Million)
• 5.4. Hospitals
  • 5.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 6. Hairy Cell Leukemia Treatment Market: Regional Estimates & Trend Analysis, By Treatment, and By End Use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.6. Singapore
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key customers
  • 7.2.3. Key company market share analysis, 2023
• 7.3. Company Profiles
  • 7.3.1. Pfizer Inc
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Product benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. F. Hoffmann La Roche AG
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Janssen Global Services
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Emcure Pharmaceuticals
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Dr. Reddy's Laboratories
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Amgen, Inc.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Hospira
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. AbbVie
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. AstraZeneca
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives

관련자료